Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Ulcerative Colitis,compared with placebo (dummy treatment) ¿ using a randomised andblinded study design (investigator and patients are not aware whetherthey receive study drug or placebo)(FIGARO UC 303).
- Conditions
- lcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- EUCTR2017-000573-37-IT
- Lead Sponsor
- SHIRE HUMAN GENETIC THERAPIES, INC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 772
Subjects must meet all of the following inclusion criteria to be eligible
for enrollment into the study.
1. Subjects and/or their parent or legally authorized representative must
have an understanding, ability, and willingness to fully comply with
study procedures and restrictions.
2. Subjects must be able to voluntarily provide written, signed, and
dated (personally or via a legally authorized representative) informed
consent and/or assent, as applicable, to participate in the study.
3. Subjects must have completed the 12 week induction treatment
period from study SHP647 301 or SHP647-302.
4. Subjects must have achieved clinical response in induction study
SHP647-301 or SHP647 302. Clinical response is defined as:
1) A decrease from the induction study (SHP647 301 or SHP647-302)
baseline in the composite score of patient-reported symptoms using
daily e-diary and centrally read endoscopy of at least 2 points and at
least 30%, with an accompanying decrease in the subscore for rectal
bleeding =1 point or a subscore for rectal bleeding =1
OR
2) A decrease from the induction study (SHP647 301 or SHP647-302)
baseline in total Mayo score of at least 3 points and at least 30%, with
an accompanying decrease in the rectal bleeding subscore of at least 1
point or an absolute rectal bleeding subscore of 0 or 1.
For eligibility assessment, clinical response will be determined based on
the centrally read endoscopy performed during screening and at Week
12 of induction study SHP647 301 or SHP647 302.
5. Subjects receiving any treatment(s) for UC described in Section 5.2.1
are eligible provided they have been, and are anticipated to be, on a
stable dose for the designated period of time.
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 679
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 16
Subjects are excluded from the study if any of the following exclusion
criteria are met:
1. Subjects who had major protocol deviation(s) (as determined by the
sponsor) in induction study SHP647 301 or SHP647 302.
2. Subjects who permanently discontinued investigational product
because of an adverse event (AE), regardless of relatedness to investigational product, in
induction study SHP647-301 or SHP647-302.
3. Subjects who are likely to require surgery for UC during the study
period.
4. Subjects are females who became pregnant during induction study
SHP647-301 or SHP647 302, females who are planning to become
pregnant during the study period, or males or females of childbearing
potential not agreeing to continue acceptable contraception methods (ie, highly effective methods for female and medically appropriate methods for male study subjects)
through the conclusion of study participation (see Section 4.4).
5. Subjects who do not agree to postpone donation of any organ or
tissue, including male subjects who are
planning to bank or donate sperm, and female subjects who are planning
to harvest or donate eggs, for the
duration of the study and through 16 weeks after last dose of
investigational product.
6. Subjects who, in the opinion of the investigator or the sponsor, will be
uncooperative or unable to comply with study procedures.
7. Subjects who have a newly diagnosed malignancy or recurrence of
malignancy (other than resected cutaneous basal cell carcinoma,
squamous cell carcinoma, or carcinoma in situ of the uterine cervix that
has been treated with no evidence of recurrence).
8. Subjects who have developed any major illness/condition or evidence
of an unstable clinical condition (eg, renal, hepatic, hematologic,
gastrointestinal (except disease under study), endocrine, cardiovascular,
pulmonary, immunologic [eg, Felty's syndrome], or local active
infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in
the study.
9. Subjects with any other severe acute or chronic medical or psychiatric
condition or laboratory or ECG abnormality that may increase the risk
associated with study participation or investigational product
administration or may interfere with the interpretation of study results
and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.
10. Subjects with known exposure to Mycobacterium tuberculosis (TB)
since testing at screening in induction study SHP647-301 or SHP647-302
and who are without a generally accepted course of treatment.
11. Subjects who are investigational site staff members or relatives of
those site staff members or subjects who are sponsor employees directly
involved in the conduct of the study.
12. Subjects who are participating in or plan to participate in other
investigational studies (other than induction study SHP647-301 or
SHP647 302) during study SHP647-303.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method